ICWEA Statement on Gilead’s announcement of twice-yearly Lenacapavir (LEN) for HIV prevention.

The International Community of Women Living with HIV Eastern Africa (ICWEA) celebrates Gilead's recent announcement regarding the twice-yearly Lenacapavir (LEN), which has demonstrated 100% efficacy and superiority over daily Truvada…

Continue ReadingICWEA Statement on Gilead’s announcement of twice-yearly Lenacapavir (LEN) for HIV prevention.